密度	2.004 g/cm3 (25 ºC)*
折射率	1.369 (589.3 nm)*

没有数据	没有数据

来源	SDS样本
没有数据	没有数据

产品合成路线

更多

名称	CAS号

更多

文章

同行评议文献

Perioperative medication withholding in patients with Parkinson's disease: a retrospective electronic health records review.Kathleen Fagerlund et al.The American journal of nursing, 113(1), 26-35 (2012-12-19) Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.L Wilson et al.Irish medical journal, 106(1), 24-25 (2013-03-12) Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).Fabrizio Stocchi et al.Clinical neuropharmacology, 33(4), 198-203 (2010-04-24) Levodopa with benserazide or carbidopa in Parkinson diseaseRinne UK and Molsa P Neurology, 29(12), 1584-1589 (1979) Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Hubert H Fernandez et al.Parkinsonism & related disorders, 19(3), 339-345 (2013-01-05) [The optimization of using levodopa in patients with Parkinson's disease: results of the OPTIMA study].V K Datieva et al.Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 13-19 (2012-12-20) Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.S Kaakkola et al.Journal of neurochemistry, 60(1), 137-144 (1993-01-01) Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies.Štefan Holiga et al.PloS one, 8(2), e56133-e56133 (2013-02-19) Chronic administration of the histamine H3 receptor agonist immepip decreases L-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats.Alberto Avila-Luna et al.Psychopharmacology, 236(6), 1937-1948 (2019-02-15) Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease.Ashok Sriram et al.Journal of neurology, 260(2), 521-527 (2012-09-26) Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.Dag Nyholm Parkinsonism & related disorders, 18(8), 916-929 (2012-07-25) Hyperdopaminergic crises in familial dysautonomia: a randomized trial of carbidopa.Lucy Norcliffe-Kaufmann et al.Neurology, 80(17), 1611-1617 (2013-04-05) The effect of carbidopa on the pharmacokinetics and metabolism of intravenously administered levodopa in blood plasma and skeletal muscle.D Deleu et al.Naunyn-Schmiedeberg's archives of pharmacology, 348(6), 576-581 (1993-12-01) Ropinirole does not affect plasma arginine vasopressin levels in patients with advanced Parkinson's disease.Motomi Arai Neuro endocrinology letters, 33(7), 680-683 (2013-02-09) Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion.Fabian Klostermann et al.Movement disorders : official journal of the Movement Disorder Society, 27(13), 1704-1705 (2012-11-30) DYT16: the original cases.Sarah Camargos et al.Journal of neurology, neurosurgery, and psychiatry, 83(10), 1012-1014 (2012-07-31) Parkinson disease treatment in hospitals and nursing facilities: avoiding pitfalls.J Eric Ahlskog Mayo Clinic proceedings, 89(7), 997-1003 (2014-07-06) Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.Giovanni Abbruzzese et al.Functional neurology, 27(3), 147-154 (2013-02-14) Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.Monica Colamartino et al.DNA and cell biology, 31(11), 1572-1579 (2012-10-02) [A combined preparation stalevo in Parkinson's disease: a 5-year experience of continuous dopaminergic stimulation].E Iu Fedotova et al.Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(5), 50-55 (2012-09-07) Extended-release carbidopa-levodopa in Parkinson's disease.Olivier Rascol The Lancet. Neurology, 12(4), 325-326 (2013-03-15) The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.Shijing Liu et al.Pharmacogenetics and genomics, 24(7), 370-373 (2014-05-09) Feasibility of carbidopa premedication in pediatric patients: a pilot study.Egesta Lopci et al.Cancer biotherapy & radiopharmaceuticals, 27(10), 729-733 (2012-10-06) Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease.Sebastiaan P van Kessel et al.Nature communications, 10(1), 310-310 (2019-01-20) Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patientsEarley CJ and Allen RP Sleep, 19(10), 801-810 (1996) Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.Robert A Hauser et al.The Lancet. Neurology, 12(4), 346-356 (2013-03-15) Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.H H Fernandez et al.Current medical research and opinion, 27(5), 907-919 (2011-03-01) Hydrogen peroxide degradation and selective carbidopa-induced cytotoxicity against human tumor lines.Judith A Gilbert et al.Biochemical pharmacology, 69(8), 1159-1166 (2005-03-30) Nitric oxide acts as a cotransmitter in a subset of dopaminergic neurons to diversify memory dynamics.Yoshinori Aso et al.eLife, 8 (2019-11-15) Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study.Francesc Valldeoriola et al.Journal of medical economics, 16(2), 191-201 (2012-10-06) Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.Ki Sung Kang et al.Brain research, 1497, 1-14 (2012-12-05) Development and validation of a simple and sensitive method for quantification of levodopa and carbidopa in rat and monkey plasma using derivatization and UPLC-MS/MS.Venkatraman Junnotula et al.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 926, 47-53 (2013-04-04) A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.Daniel Kiblboeck et al.BMJ case reports, 2012, doi:10-doi:10 (2012-08-29) Levodopa/carbidopa to improve motor function subsequent to brain tumor excision.Jesse D Ennis et al.American journal of physical medicine & rehabilitation, 92(4), 307-311 (2012-12-12) Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa® therapy.Sabine Skodda et al.Journal of neural transmission (Vienna, Austria : 1996), 120(2), 315-318 (2012-07-17) Drug-induced burning mouth syndrome: a new clinico-pathological entity?Giulio Fortuna et al.The journal of headache and pain, 13(8), 685-686 (2012-10-12) Assuring the quality of next-generation sequencing in clinical laboratory practice.Amy S Gargis et al.Nature biotechnology, 30(11), 1033-1036 (2012-11-10)

备注